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INTRODUCTION
Due to the risk of hypoglycemia, safe, effective and reproducible
tight glycemic control (TGC) has proven challenging in the
intensive care unit (ICU). Hence, based on recent clinical trials,
there is a trend toward less rigid blood glucose (BG) targets1.
Based on new guidelines for inpatient glycemic management,
the Yale ICU insulin infusion protocol was revised to achieve a
higher BG target of 120-160mg/dL (Yale 2009). The safety and
efficacy of the Yale 2009 protocol was evaluated in silico and
compared with the earlier Yale 2005 protocol2 that targeted 90-
120mg/dL.
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METHODS
Insulin-glucose modeling was used to create ‘virtual
patients’ and simulate expected glycemic responses
to different insulin protocols. To validate the
simulation system for the Yale Protocol, simulation
results were compared to reported clinical results
for the Yale 2005 protocol (Figure 1):
• Clinical data from 54 US cardiac surgery patients
treated with the Yale 2005 protocol2
• Virtual patients generated from 40 New Zealand
cardiac surgery patients treated with the SPRINT
insulin-dextrose infusion protocol3
Next, the Yale 2009 protocol was simulated on the
virtual cohort and compared to the Yale 2005. The
system model (Figure 2) has been previously
validated in silico, versus the euglycemic clamp and
in several real-time clinical TGC trials in adults and
neonates4. To aid direct comparison to the 54-
patient clinical results, the 40 patient virtual cohort
was re-sampled to create 1,000 54-patient cohorts
using the bootstrapping method with replacement.
RESULTS
Yale 2005 
(90 – 120 mg/dL)
Yale 2009
(120 – 160 mg/dL)
Clinical Simulated Simulated
Number of patients 54 54 54
Mean initial BG level (mg/dL) 189 188 185
SD Initial BG level (mg/dL) 44 35 30
Median time on protocol (hours) 15 15 18
Median time to target (<120 mg/dL) 6 hours 4 hours -
Median time to target (<160 mg/dL) - - 2 hours
Median time to < 140 mg/dL (hours) 5 hours 3 hours 3 hours
Following highlighted results are after 
respective target achieved:
% BGs within 80 - 139 mg/dL 86 78 66
% BGs within 80 - 199 mg/dL 95 90 99.8
% BGs within 90 - 119 mg/dL 60 50 27
% BGs within 100 - 139 mg/dL 66 51 56
Mean BG (per-patient) (mg/dL) 109 109 130
Mean BG (cohort) (mg/dL) 112 110 130
Hypoglycemia (BG < 60 mg/dL)
% of BG measurements 0.3 0.6 0.0
# of patients 3 4 0
# of ICU patient days 3.7 4.0 0.0
Number of measurements after target 679 708 866
Measurements per hour  0.961 0.938
Median BG (overall) (mg/dL) 117 135
Mean BG (overall) (mg/dL) 124 137
% BGs within target range
After target achieved 51 56
Overall 37 48
Clinical vs. simulated results
BG outcomes for the Yale 2005 clinical
results and simulations on the virtual patient
cohort were very similar (Table 1):
• Mean BG levels within 1-2 mg/dL.
• Hypoglycemia rates closely matched to
the observed clinical incidence.
The New Zealand SPRINT clinical patients
and, as a result, the in silico cohorts,
exhibited some differences to US Yale clinical
patients:
• Higher sensitivity to insulin
• Reduced time to BG target
• Lower BMI
Overall, the well-matched results
demonstrate the ability of the in silico model
to capture Yale 2005’s fundamental glycemic
dynamics and outcomes.
Yale 2009 simulations
The Yale 2009 simulation results predict
expected shifts in glucose control (Table 1):
• Median BG of 135mg/dL (128mg/dL
after reaching target)
• Essentially no hypoglycemia.
• Possible reduction in BG fingersticks
per hour
Additionally, distributions of simulated BG
measurements indicates that the Yale 2009
protocol will effectively shift glycemic levels to
the new higher target range (Figure 3).
Table 1: Clinical results for Yale 2005 compared to simulated glycemic outcomes for Yale 2005 and 2009
protocols. Highlighted results indicate metrics are computed once patient has reached target BG band for
consistency with reported clinical results2. ‘Overall’ indicates data used for entire simulated protocol usage
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Figure 2: Overall insulin-glucose model employed in this study.
Model-fitted insulin sensitivity parameter (SI) indicates influence of insulin on glucose
concentration (G) via uptake by insulin-dependent mechanisms. Simulated insulin kinetics
are governed by the model equations for (I) and (Q), plasma and interstitial insulin.
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CONCLUSIONS
•The in silico analysis indicates that the Yale 2009 protocol will reduce hypoglycemia
without increasing BG measurement burden, and will maintain glycemia within a
new higher target range.
•In silico simulation and analysis is a highly effective tool to design, evaluate and
optimize protocols prior to clinical implementation.
Figure 1: Simulation method for in-
silico protocol comparison.
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Figure 3: Distribution of simulated BG measurements for Yale
2005 (top panel, blue) and Yale 2009 (bottom panel, red).
